Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial

Study limitation reported by the research below: “The 'practice changing' impact flag reflects the large and statistically significant effect size in a phase 2 trial, but full clinical adoption should await phase 3 confirmation. Flag used cautiously.”